OTCQB: OXIS

Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline

About

OXIS International, Inc., develops and commercializes innovative immunotherapeutic for the treatment of cancer and other unmet medical needs.

learn more
About
Technology

Technology

Antibody-drug conjugates are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of cancer.

learn more

Latest News

Oxis Enters into a Co-Development Partnership Agreement with Altor Bioscience for Novel TriKE Therapeutic
Jun 13, 2017 • 8:30 EDT | Read More

Oxis International Inc. Announces Treatment of First Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550
Apr 18, 2017 • 9:45 EDT | Read More

Investors

OXIS International Inc. OTCQB: OXIS
Loading... Change
Loading... Volume
Loading... 52 Week Range